Navigation Links
Byetta Lawsuit News: Bernstein Liebhard LLP Awaits Decision on Establishment of Federal Multidistrict Litigation for Byetta Pancreatic Cancer Claims
Date:7/20/2013

New York, New York (PRWEB) July 20, 2013

As Byetta lawsuit claims continue to mount in courts throughout the country, Bernstein Liebhard LLP notes that the U.S. Judicial Panel on Multidistrict Litigation (JPML) is scheduled to hear Oral Arguments on July 25th regarding the possible establishment of a multidistrict litigation for all federal product liability claims involving Byetta and other type 2 diabetes drugs known as incretin mimetics. On April 29, Amylin and Eli Lilly, the manufacturers of Byetta, filed a response with the JPML voicing support for the proposed litigation. The companies also agreed that the U.S. District Court, Southern District of California would be the appropriate venue for the litigation. (In Re: Incretins Products Liability, Sales and Marketing Litigation, MDL 2452, JPML)

“We have received numerous inquiries from individuals seeking to file Byetta pancreatic cancer lawsuits, and continue to hear from others who allegedly developed pancreatitis or thyroid cancer due to this drug. We look forward to the Panel’s decision regarding the consolidation of these cases,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free Byetta lawsuit evaluations to patients who took this drug and were diagnosed with pancreatic cancer, thyroid cancer or pancreatitis.

Byetta Pancreatic Cancer Lawsuits
According to the Amylin and Eli Lilly filing, the companies have been named defendants in at least 42 Byetta pancreatic cancer lawsuits filed in courts throughout the country. All of the claims allege the companies concealed the association between Byetta and pancreatic cancer, and failed to provide adequate warnings regarding the drug’s risks.

Over the past several months, Byetta and other incretin mimetics have come under scrutiny, as concerns have mounted over their potentially harmful effects on the pancreas. On March 14, the U.S. Food & Drug Administration (FDA) announced it was investigating findings from an unpublished study that suggested Byetta and other incretin mimetics could be associated with pre-cancerous cellular changes in the pancreas called pancreatic duct metaplasia.* The month prior, a paper published in JAMA Internal Medicine reported that drugs like Byetta appeared to double the risk for pancreatitis, a known risk factor for pancreatic cancer.** A year earlier, research published in Gastroenterology found that Byetta increased the risk of pancreatic cancer by nearly 3-fold. The same study also reported 30 cases of thyroid cancer in patients taking the drug, and a six-fold increase risk for pancreatitis among Byetta users.***

According to Bernstein Liebhard LLP, multidistrict litigations like that proposed for Byetta lawsuits are established when a large number of complex cases share common allegations of facts. The aim of such a proceeding is to preserve the resources of the Court, parties and witnesses, and to avoid duplicative discovery and conflicting orders.

Byetta users who developed pancreatic cancer, pancreatitis or thyroid cancer may be entitled to compensation for medical bills, lost wages, and pain and suffering. Additional information about filing a Byetta lawsuit is available at Bernstein Liebhard LLP’s website. To learn more, please call 800-511-5092.

*fda.gov/Drugs/DrugSafety/ucm343187.htm, FDA, March 14, 2013
**archinte.jamanetwork.com/article.aspx?articleid=1656537, JAMA Internal Medicine, February 25, 2013
***gastrojournal.org/article/S0016-5085%2811%2900172-7/abstract, Gastroenterology, February 21, 2011

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 10 consecutive years.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092

ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com
http://www.byettalawsuit2013.com/

Read the full story at http://www.prweb.com/releases/byetta-lawsuit/byetta-pancreatic-cancer/prweb10948003.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. d'Oliveira & Associates Releases New Byetta Infographic on Potential Kidney and Pancreas Health Risks Associated with the Drug
2. Byetta Pancreatic Cancer Allegation Lawsuits Offered through Resource4thePeople
3. DrugRisk Announces Launch of Byetta Cancer Resource Center
4. Pancreatic Cancer Correlation to Type 2 Diabetes Drugs Januvia and Byetta, New Studies Find Possible Connection
5. DrugRisk Update: New Study Warns of Cancer in Byetta Side Effects
6. Byetta Lawsuit News: Woman Alleges Her Thyroid Cancer Is Linked to Byetta Use, Rottenstein Law Group LLP Reports
7. DrugRisk Update: Byetta Maker Agrees With Transferring Lawsuits to Federal Court
8. Byetta Lawyers at Gilman Law, a Leading Pharmacy Law and Defective Drug Plaintiffs’ Law Firm, Troubled by Growing Byetta Pancreatic Cancer Reports
9. Diabetes Drug Byetta Caused Arkansas Man’s Pancreatic Cancer and Resulting Injuries, Alleges Lawsuit Filed by Parker Waichman LLP and Co-Counsel
10. Rottenstein Law Group LLP Comments on Drugmakers’ Cooperation With Safety Review of Byetta, Januvia, Victoza
11. Byetta Pancreatic Cancer Lawsuit News: Bernstein Liebhard LLP Comments on BMJ Investigation Finding Incretin Mimetic Risks Were Downplayed
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... ... May 27, 2016 , ... Aimed at nurses and employees ... which come courtesy of leaders in the nursing and health care industry. It also ... and associations—namely Abilene Christian University. , As the nursing industry is coming out ...
(Date:5/26/2016)... ... May 26, 2016 , ... Despite last week’s media reports hinting at a ... to wait until March 2017 for an interest rate increase, according to Rajeev Dhawan ... Business. , “The Federal Open Market Committee (FOMC) dot charts are of interest to ...
(Date:5/26/2016)... California (PRWEB) , ... May 26, 2016 , ... ... associated with discovery of thousands of defective respirators, according to court documents and ... the case of William and Becky Tyler v. American Optical Corporation, Case No. ...
(Date:5/26/2016)... ... ... Connor Sports, through its Connor Cares initiative, will continue to ... Legacy Tour that will commemorate the Indiana Fever legend’s hall-of-fame career and final ... and levels of the game, Connor Sports has committed to a significantly increased focus ...
(Date:5/26/2016)... ... May 26, 2016 , ... Cardiac arrhythmia is ... impact on long-term patient survival, reports a team of UPMC researchers in the ... in the Journal of Thoracic and Cardiovascular Surgery, provide critical information that will ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... 25,2016 FDA 510(k) clearance ... platform for urological and surgical applications ... of Cellvizio®, the multidisciplinary confocal laser endomicroscopy (CLE) ... the US with the 12 th 510(k) ... (FDA). This new FDA clearance covers Confocal Miniprobes ...
(Date:5/25/2016)... May 25, 2016  Zymo Research Corp. announced ... new reference materials that help researchers obtain the ... to analyses. The rapid growth of the study ... to have standard methods to improve the reproducibility ... inherently exist at every step of the measurement ...
(Date:5/25/2016)... , May 25, 2016  Granger Diagnostics today announced ... for wounds and infections. This test ensures discovery ... select viruses. The test requires only a simple swab ... David G. Bostwick , MD, Chief ... facilitate wound healing: "We are excited to make ...
Breaking Medicine Technology: